Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials
JCO Clinical Cancer Informatics · 2025
DOI: 10.1200/cci.24.00114 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JCO Clinical Cancer Informatics, 2025. Verfasst von Danielle Lilly Nicholls und 16 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cetuximab, Colorectal Neoplasms, Machine Learning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Cetuximab (CET), targeting the epidermal growth factor receptor, is a systemic treatment option for patients with colorectal cancer. One known predictive factor for CET efficacy is the presence of CET-related rash; other putative toxicity factors include fatigue and nausea. Analysis of early CET-associated toxicities may reveal patient subpopulations that clinically benefit from long-term CET treatment. METHODS We analyzed data from CO.20 (ClinicalTrials.gov identifier: NCT00640471 ) trial arms, CET + brivanib alaninate (BRIV) (n = 376) and CET + placebo (n = 374), and CO.17 (ClinicalTrials.gov identifier: NCT00079066 ) trial arms, CET (+best supportive care [BSC]; n = 287) and BSC only (n = 285). Patients were clustered into subpopulations using KmL3D, a machine learning method, to analyze 14 joint longitudinal toxicity trajectories from weeks 0 to 8 of treatment. Landmark survival analyses were performed from 8 weeks after treatment initiation. Regression analyses assessed the relationship between subpopulations and plasma CET concentrations. Three supervised machine learning models were developed to assign patients in the CO.20-CET trial arm into subpopulations, which were then validated using CO.20-CET-BRIV and CO.17-CET trial arm data. RESULTS Joint longitudinal toxicity clustering revealed dichotomous high- and low-toxicity clusters, with all CET-containing arms showing consistent toxicity trajectories and characteristics. High-toxicity clusters were associated with male predilection, fewer metastatic sites, fewer colon-only primaries, and higher body mass indices. In CO.20 trial samples, higher toxicity clusters were associated with improved overall survival and progression-free survival outcomes (adjusted hazard ratios ranging from 2.21 to 4.36) and higher CET concentrations ( P = .003). The random forest predictive model performed the best, with an AUC of 0.981 (0.963-0.999). CONCLUSION We used an innovative machine learning approach to analyze longitudinal joint drug toxicities, demonstrating their role in predicting patient outcomes through a putative pharmacokinetic mechanism.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
- Cabrini Hospital and Monash University, Melbourne, VIC, Australia.
- Flinders Medical Centre and Flinders University, Adelaide, SA, Australia.
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
ORCID-Profile: Danielle Lilly Nicholls, Maria C Xu, Luna Zhan, M Catherine Brown, Christos S Karapetis, John Simes, Dongsheng Tu, Eric Chen, Geoffrey Liu
Zitieren
APA
Nicholls, D. L., Xu, M. C., Zhan, L., Sharma, D., Hueniken, K., Chiasson, K., Wahba, M., Brown, M. C., Grant, B., Shapiro, J., Karapetis, C. S., Simes, J., Jonker, D., Tu, D., O'Callaghan, C., Chen, E., & Liu, G. (2025). Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci.24.00114
Vancouver
Nicholls DL, Xu MC, Zhan L, Sharma D, Hueniken K, Chiasson K, et al. Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci.24.00114
BibTeX
@article{Nicholls2025,
author = {Nicholls, Danielle Lilly and Xu, Maria C and Zhan, Luna and Sharma, Divya and Hueniken, Katrina and Chiasson, Kaitlyn and Wahba, Mary and Brown, M Catherine and Grant, Benjamin and Shapiro, Jeremy and Karapetis, Christos S and Simes, John and Jonker, Derek and Tu, Dongsheng and O'Callaghan, Christopher and Chen, Eric and Liu, Geoffrey},
title = {Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
doi = {10.1200/cci.24.00114}
}
EUVIMED